Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 24035405

Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2013 Oct
First author
Calabrò L

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2013 Oct;14(11):1035-1037. doi: 10.1016/S1470-2045(13)70401-7.
    note
    Source null
    related pmid
    24035406
    relationship
    Comment in
  2. citation
    Lancet Oncol. 2014 Jan;15(1):e1. doi: 10.1016/S1470-2045(13)70557-6.
    note
    Source null
    related pmid
    24384488
    relationship
    Comment in
  3. citation
    Lancet Oncol. 2014 Jan;15(1):e1-2. doi: 10.1016/S1470-2045(13)70573-4.
    note
    Source null
    related pmid
    24384489
    relationship
    Comment in

Authors and identifiers

  1. name
    Calabrò L
    type
    Author
  2. name
    Morra A
    type
    Author
  3. name
    Fonsatti E
    type
    Author
  4. name
    Cutaia O
    type
    Author
  5. name
    Amato G
    type
    Author
  6. name
    Giannarelli D
    type
    Author
  7. name
    Di Giacomo AM
    type
    Author
  8. name
    Danielli R
    type
    Author
  9. name
    Altomonte M
    type
    Author
  10. name
    Mutti L
    type
    Author
  11. name
    Maio M
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Calabrò L
    type
    Author
  2. name
    Morra A
    type
    Author
  3. name
    Fonsatti E
    type
    Author
  4. name
    Cutaia O
    type
    Author
  5. name
    Amato G
    type
    Author
  6. name
    Giannarelli D
    type
    Author
  7. name
    Di Giacomo AM
    type
    Author
  8. name
    Danielli R
    type
    Author
  9. name
    Altomonte M
    type
    Author
  10. name
    Mutti L
    type
    Author
  11. name
    Maio M
    type
    Author
bibliography ids
  1. nci-bib-5b002ef2d8a36af5f947402d
book metadata
content sha256
dc18c259b6d27b63d733bf19429ba911087748bb8ccc1152f481a1f201f69afa
document type
citation
dois
  1. 10.1016/S1470-2045(13)70381-4
electronic publication date
display
2013 Sep 11
precision
day
year
2013
evidence scope
bibliographic_metadata_only
id
pubmed:24035405
immutable id
pubmed:24035405@dc18c259b6d27b63d733bf19429ba911087748bb8ccc1152f481a1f201f69afa
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
11
name
The Lancet. Oncology
nlm unique id
100957246
pages
1104-1111
volume
14
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2013 Oct;14(11):1035-1037. doi: 10.1016/S1470-2045(13)70401-7.
    note
    Source null
    related pmid
    24035406
    relationship
    Comment in
  2. citation
    Lancet Oncol. 2014 Jan;15(1):e1. doi: 10.1016/S1470-2045(13)70557-6.
    note
    Source null
    related pmid
    24384488
    relationship
    Comment in
  3. citation
    Lancet Oncol. 2014 Jan;15(1):e1-2. doi: 10.1016/S1470-2045(13)70573-4.
    note
    Source null
    related pmid
    24384489
    relationship
    Comment in
outcomes validated
false
pmid
24035405
provenance
batch id
0a08f044391426feb8ef
provider
NCBI PubMed ESummary
record sha256
6dcf44091a2e1401f13f2042749d9114c6c3e49b707c74585f7fde1038232572
response sha256
d94e6242343e5962374663e5e5f0191e7b595329228d2e360db95a280e588409
retrieved at
2026-09-09T23:46:57.614689+00:00
publication date
display
2013 Oct
precision
month
year
2013
publication types
  1. Clinical Trial, Phase II
  2. Journal Article
  3. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/24035405/
title
Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial.

Preserved source evidence · Not medical advice